FDA clears F18-FLT
"FDA approval of a multicenter investigational new drug application has cleared away regulatory obstacles that stood in the way of definitive trials to establish the clinical efficacy of a PET imaging agent that measures cell proliferation in cancerous tumors.Molecular imaging researchers have touted F-18-labeled 3'-deoxy-3'-fluorothymidine (FLT) for the potential complementary role it could play with FDG for cancer imaging. "
Complete article here-
FDA clears F18-FLT
![]()
Reviewed by Sumer Sethi
on
Wednesday, February 11, 2009
Rating:
Sumer Sethi
Unique blend of academic excellence and entrepreneurship, heading leading firms in India- Teleradiology Providers, pioneering company providing teleradiology services and DAMS (Delhi Academy of Medical Sciences) Premier test preparation institute in India for MD/MS/MCI preparation. He has also been an invited faculty member at various conferences, including Teleradiology in IRIA 2008 and 2011, Hospital Build Middle East, Congress of the Brain Tumor Radiology in Neuro-oncology Society. Dr. Sethi is Editor-in-Chief of Internet Journal of Radiology. He has a keen interest in Web 2.0 technologies and in maintaining his famous radiology blog, which has been featured in multiple international journals.
No comments:
Post a Comment